{"id":"NCT04927065","sponsor":"ModernaTX, Inc.","briefTitle":"A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants","officialTitle":"A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2021-05-28","primaryCompletion":"2023-11-17","completion":"2023-11-17","firstPosted":"2021-06-15","resultsPosted":"2025-02-28","lastUpdate":"2025-02-28"},"enrollment":5161,"design":{"allocation":"NON_RANDOMIZED","model":"SEQUENTIAL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["SARS-CoV-2"],"interventions":[{"type":"BIOLOGICAL","name":"mRNA-1273.211","otherNames":[]},{"type":"BIOLOGICAL","name":"mRNA-1273","otherNames":[]},{"type":"BIOLOGICAL","name":"mRNA-1273.617.2","otherNames":[]},{"type":"BIOLOGICAL","name":"mRNA-1273.213","otherNames":[]},{"type":"BIOLOGICAL","name":"mRNA-1273.529","otherNames":[]},{"type":"BIOLOGICAL","name":"mRNA-1273.214","otherNames":[]},{"type":"BIOLOGICAL","name":"mRNA-1273.222","otherNames":[]},{"type":"BIOLOGICAL","name":"mRNA-1273.815","otherNames":[]},{"type":"BIOLOGICAL","name":"mRNA-1273.231","otherNames":[]}],"arms":[{"label":"Part A.1: mRNA-1273.211 50 μg","type":"EXPERIMENTAL"},{"label":"Part A.1: mRNA-1273.211 100 μg","type":"EXPERIMENTAL"},{"label":"Part B: mRNA-1273 100 μg","type":"EXPERIMENTAL"},{"label":"Part C: mRNA-1273.617.2 100 μg","type":"EXPERIMENTAL"},{"label":"Part C: mRNA-1273.617.2 50 μg","type":"EXPERIMENTAL"},{"label":"Part D: mRNA-1273.213 50 μg","type":"EXPERIMENTAL"},{"label":"Part D: mRNA-1273.213 100 μg","type":"EXPERIMENTAL"},{"label":"Part E: mRNA-1273.213 100 μg","type":"EXPERIMENTAL"},{"label":"Part F Cohort 1: mRNA-1273.529 50 μg","type":"EXPERIMENTAL"},{"label":"Part F Cohort 2: mRNA-1273.529 50 μg and mRNA-1273 50 μg","type":"EXPERIMENTAL"},{"label":"Part G: mRNA-1273.214 50 μg","type":"EXPERIMENTAL"},{"label":"Part A.2: mRNA-1273.214 50 μg","type":"EXPERIMENTAL"},{"label":"Part H: mRNA-1273.222 50 μg","type":"EXPERIMENTAL"},{"label":"Part J: mRNA-1273.815 or mRNA-1273.231","type":"EXPERIMENTAL"}],"summary":"This is a study to evaluate the immunogenicity, safety, and reactogenicity of mRNA-1273.211, mRNA-1273, mRNA-1273.617.2, mRNA-1273.213, mRNA-1273.529, mRNA-1273.214, mRNA-1273.222, mRNA-1273.815, and mRNA-1273.231 administered as booster doses.","primaryOutcome":{"measure":"Number of Participants With Solicited Local and Systemic ARs","timeFrame":"7 days post-vaccination","effectByArm":[{"arm":"Part A.1: mRNA-1273.211 50 μg","deltaMin":270,"sd":null},{"arm":"Part A.1: mRNA-1273.211 100 μg","deltaMin":554,"sd":null},{"arm":"Part A.2: mRNA-1273.214 50 μg","deltaMin":113,"sd":null},{"arm":"Part B: mRNA-1273 100 μg","deltaMin":290,"sd":null},{"arm":"Part C: mRNA-1273.617.2 50 μg","deltaMin":532,"sd":null},{"arm":"Part C: mRNA-1273.617.2 100 μg","deltaMin":548,"sd":null},{"arm":"Part D: mRNA-1273.213 50 μg","deltaMin":307,"sd":null},{"arm":"Part D: mRNA-1273.213 100 μg","deltaMin":550,"sd":null},{"arm":"Part E: mRNA-1273.213 100 μg","deltaMin":41,"sd":null},{"arm":"Part F (Cohort 1): mRNA-1273.529 50 μg","deltaMin":113,"sd":null},{"arm":"Part F (Cohort 2): mRNA-1273 50 μg","deltaMin":300,"sd":null},{"arm":"Part F (Cohort 2): mRNA-1273.529 50 μg","deltaMin":323,"sd":null},{"arm":"Part G: mRNA-1273.214 50 μg","deltaMin":380,"sd":null},{"arm":"Part H: mRNA-1273.222 50 μg","deltaMin":443,"sd":null},{"arm":"Part J: mRNA-1273.231 50 μg","deltaMin":44,"sd":null},{"arm":"Part J: mRNA-1273.815 50 μg","deltaMin":38,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":2,"exclusionCount":11},"locations":{"siteCount":23,"countries":["United States"]},"refs":{"pmids":["37653342","36112399","35291289"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":300},"commonTop":["COVID-19","Upper respiratory tract infection","Asymptomatic COVID-19","Fatigue","Rhinovirus infection"]}}